Cargando…

Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome

BACKGROUND: Some drugs for irritable bowel syndrome (IBS) have serious side effects. AIMS: To examine the willingness of individuals with IBS to accept risks with medication in return for symptom cure. METHODS: We collected demographic, gastrointestinal symptoms, psychological health, quality of lif...

Descripción completa

Detalles Bibliográficos
Autores principales: Goodoory, Vivek C., Ng, Cho Ee, Black, Christopher J., Ford, Alexander C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303338/
https://www.ncbi.nlm.nih.gov/pubmed/35166374
http://dx.doi.org/10.1111/apt.16816
_version_ 1784751839896403968
author Goodoory, Vivek C.
Ng, Cho Ee
Black, Christopher J.
Ford, Alexander C.
author_facet Goodoory, Vivek C.
Ng, Cho Ee
Black, Christopher J.
Ford, Alexander C.
author_sort Goodoory, Vivek C.
collection PubMed
description BACKGROUND: Some drugs for irritable bowel syndrome (IBS) have serious side effects. AIMS: To examine the willingness of individuals with IBS to accept risks with medication in return for symptom cure. METHODS: We collected demographic, gastrointestinal symptoms, psychological health, quality of life and impact on work and daily activities data from 752 adults with Rome IV‐defined IBS. We examined median willingness to accept death in return for cure with a hypothetical medication using a standard gamble, according to these variables. RESULTS: Participants would accept a median 2.0% (IQR 0.0%‐9.0%) risk of death in return for a 98.0% (IQR 91.0%‐100.0%) chance of permanent symptom cure. The median accepted risk of death was higher in men (5.0% vs 2.0%, P < 0.001), those with continuous abdominal pain (4.0% vs 1.0%, P < 0.001), more severe symptoms (P = 0.005 for trend), abnormal depression scores (P < 0.001 for trend), higher gastrointestinal symptom‐specific anxiety (P < 0.001 for trend), and lower IBS‐related quality of life (P < 0.001 for trend). Those willing to accept above median risk of death were more likely to be male (17.1% vs 9.1%, P < 0.001), take higher levels of risks in their daily life (P = 0.008 for trend), and report continuous abdominal pain (53.1% vs 39.4%, P < 0.001), and had higher depression (P = 0.004 for trend) and lower quality of life (P < 0.001 for trend) scores. CONCLUSION: Patients are willing to accept significant risks in return for cure of their IBS symptoms.
format Online
Article
Text
id pubmed-9303338
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93033382022-07-22 Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome Goodoory, Vivek C. Ng, Cho Ee Black, Christopher J. Ford, Alexander C. Aliment Pharmacol Ther Willingness to Accept Risk in IBS BACKGROUND: Some drugs for irritable bowel syndrome (IBS) have serious side effects. AIMS: To examine the willingness of individuals with IBS to accept risks with medication in return for symptom cure. METHODS: We collected demographic, gastrointestinal symptoms, psychological health, quality of life and impact on work and daily activities data from 752 adults with Rome IV‐defined IBS. We examined median willingness to accept death in return for cure with a hypothetical medication using a standard gamble, according to these variables. RESULTS: Participants would accept a median 2.0% (IQR 0.0%‐9.0%) risk of death in return for a 98.0% (IQR 91.0%‐100.0%) chance of permanent symptom cure. The median accepted risk of death was higher in men (5.0% vs 2.0%, P < 0.001), those with continuous abdominal pain (4.0% vs 1.0%, P < 0.001), more severe symptoms (P = 0.005 for trend), abnormal depression scores (P < 0.001 for trend), higher gastrointestinal symptom‐specific anxiety (P < 0.001 for trend), and lower IBS‐related quality of life (P < 0.001 for trend). Those willing to accept above median risk of death were more likely to be male (17.1% vs 9.1%, P < 0.001), take higher levels of risks in their daily life (P = 0.008 for trend), and report continuous abdominal pain (53.1% vs 39.4%, P < 0.001), and had higher depression (P = 0.004 for trend) and lower quality of life (P < 0.001 for trend) scores. CONCLUSION: Patients are willing to accept significant risks in return for cure of their IBS symptoms. John Wiley and Sons Inc. 2022-02-15 2022-05 /pmc/articles/PMC9303338/ /pubmed/35166374 http://dx.doi.org/10.1111/apt.16816 Text en © 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Willingness to Accept Risk in IBS
Goodoory, Vivek C.
Ng, Cho Ee
Black, Christopher J.
Ford, Alexander C.
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome
title Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome
title_full Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome
title_fullStr Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome
title_full_unstemmed Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome
title_short Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome
title_sort willingness to accept risk with medication in return for cure of symptoms among patients with rome iv irritable bowel syndrome
topic Willingness to Accept Risk in IBS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303338/
https://www.ncbi.nlm.nih.gov/pubmed/35166374
http://dx.doi.org/10.1111/apt.16816
work_keys_str_mv AT goodooryvivekc willingnesstoacceptriskwithmedicationinreturnforcureofsymptomsamongpatientswithromeivirritablebowelsyndrome
AT ngchoee willingnesstoacceptriskwithmedicationinreturnforcureofsymptomsamongpatientswithromeivirritablebowelsyndrome
AT blackchristopherj willingnesstoacceptriskwithmedicationinreturnforcureofsymptomsamongpatientswithromeivirritablebowelsyndrome
AT fordalexanderc willingnesstoacceptriskwithmedicationinreturnforcureofsymptomsamongpatientswithromeivirritablebowelsyndrome